Navigation Links
Newly identified role for 'power plants' in human cells could lead to targeted therapies
Date:6/24/2008

COLUMBUS, Ohio Scientists have determined that human cells are able to shift important gene products into their own mitochondria, considered the power plants of cells. The finding could eventually lead to therapies for dozens of diseases.

The gene products, known as tRNAs, assemble amino acids for the production of proteins within mitochondria. If the mitochondrial tRNA genes are defective or missing, and proteins are not manufactured, the mitochondria are unable to generate adequate energy.

Defective tRNAs are believed to be the cause of about 60 percent of conditions traced to malfunctions in the mitochondria. The range of related conditions includes diabetes, hearing loss and a number of neurological disorders, depending on which kinds of cells are affected.

Mitochondria are encased in their own membrane, making them a structure that is complicated to study. Previous research has suggested that only in lower organisms, such as protozoans, yeast and plants, can tRNAs be imported to the mitochondria from the cell cytoplasm, the fluid-based area that contains most components of a cell.

But in this new research, scientists determined that tRNAs can be imported from cytoplasm to mitochondria in rat liver cells and human cells as well.

"This was totally unexpected, to find an innate, built-in mechanism that we humans have," said Juan Alfonzo, senior author of the study and an assistant professor of microbiology at Ohio State University. The finding broadens the study of therapeutic options involving attempts to introduce healthy tRNAs to the defective mitochondria of ill patients, Alfonzo said.

"If you have a mutation in a tRNA that you suspect is involved in disease, you theoretically should be able to bring a healthy tRNA from the cytoplasm into the mitochondria and correct the malfunction," he said.

The research appears online this week in the Proceedings of the National Academy of Sciences.

Alfonzo noted that the current study was able to determine that the import of tRNAs occurs, but it leaves open the question of how it happens.

He and colleagues conducted experiments first in rat liver cells to test whether tRNA import occurs in mammals at all. When the import was observed in rat mitochondria, they extended the study to human cells.

The finding that tRNA import occurs in humans can set in motion an entirely new line of research into therapeutic options for patients with diseases caused by mitochondrial defects. There appears to be no way to introduce healthy tRNAs directly into mitochondria because their membranes have proven impenetrable to such outside interference, Alfonzo explained.

So scientists know they would have to rely on the import process that starts in the cytoplasm to transfer healthy tRNAs to damaged mitochondria and improve energy production.

Until now, researchers didn't know the human mitochondria had that import ability, so scientists were going to try using protozoan or yeast cells to manipulate the import process in human cells.

"What we are saying is you don't need to bring up new machinery from a different organism because human cells already come equipped with their own way to import tRNAs. There is no need to cross species," Alfonzo said. "What we need to know now is what proteins are involved in the import mechanism so we can exploit the process for therapy."

One compound already identified as essential for the process is Adenosine-5-triphosphate, or ATP, a compound associated with energy transport in cells. Alfonzo and colleagues demonstrated ATP's role in the process using cells from a patient with a specific type of epilepsy called MERRF. This disease is characterized by a mitochondrial tRNA mutation leading to a drastic reduction in the mitochondria's ability to generate ATP, which in turn hinders the import of tRNAs into the mitochondria of people with this disease.

When ATP was introduced to the mitochondria of these diseased cells, the import process of tRNAs from the cytoplasm to the mitochondria was restored.

"These were cells from an actual patient, so this also makes the argument that we don't need a surrogate system from other organisms to set the import process in motion," Alfonzo said.


'/>"/>

Contact: Juan Alfonzo
Alfonzo.1@osu.edu
614-292-0004
Ohio State University
Source:Eurekalert

Related biology news :

1. Newly defined signaling pathway could mean better biofuel sources
2. Newly-identified exercise gene could help with depression
3. Newly created cancer stem cells could aid breast cancer research
4. Threatened or invasive? Species fates identified
5. A new gene trigger for pregnancy disorder identified
6. Ovarian cancer stem cells identified, characterized
7. Promising new drug targets identified for Huntingtons disease
8. DNA barcode identified for plants
9. Novel mechanism for long-term learning identified by Carnegie Mellon researchers
10. Cognitive, genetic clues identified in imaging study of alcohol addiction
11. Mutant gene identified as villain in hardening of the arteries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ON , June 27, 2016 /PRNewswire/ - BIOREM Inc. ... has been advised by its major shareholders, Clean Technology ... United States based venture capital ... shares of Biorem (on a fully diluted, as converted ... the disposition of their entire equity holdings in Biorem ...
(Date:6/27/2016)... N.C. (PRWEB) , ... June 27, 2016 , ... ... commercial operations for Amgen, will join the faculty of the University of ... as adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology: